Abstract
This is a Phase 2, double-blind, randomized clinical trial to explore the safety,
tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric participants who have
seizures associated with early-onset SCN2A-DEE and SCN8A-DEE.
